Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

Completed · Phase 1/Phase 2

Conditions studied: Aging

In brief

The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.

Key facts

Study ID
NCT05422885
Run by
Lewis Lipsitz
People needed
15
Starts
2022-05-20
Expected to finish
2024-01-24
Last updated by the study team
2025-03-17

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.